Complete Eisai Co. Ltd. stock information by Barron's. View real-time 4523 stock price and news, along with industry-best analysis.

DAYVIGO is a dual orexin receptor antagonist that inhibits orexin neurotransmission regulating sleep-wake rhythm by binding competitively to the two subtypes of orexin receptors (OX1R and OX2R).

GUILDFORD, UNITED KINGDOM / ACCESS Newswire / May 28, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in ...

Japanese drugmaker Eisai (TYO: 4523) today announced that the in-house-discovered and developed orexin receptor antagonist ...